Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) has been given a consensus rating of “Buy” by the eight analysts that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have covered the stock in the last year is $91.30.
A number of equities analysts have commented on RARE shares. StockNews.com started coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, October 5th. They set a “hold” rating for the company. HC Wainwright restated a “buy” rating and set a $82.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 1st. Cantor Fitzgerald restated an “overweight” rating and set a $114.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Monday, September 25th. Morgan Stanley cut their price target on shares of Ultragenyx Pharmaceutical from $90.00 to $84.00 and set an “overweight” rating for the company in a report on Friday, November 3rd. Finally, Piper Sandler cut their price target on shares of Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating for the company in a report on Wednesday, October 25th.
Insider Activity at Ultragenyx Pharmaceutical
Institutional Investors Weigh In On Ultragenyx Pharmaceutical
Hedge funds have recently modified their holdings of the company. Truist Financial Corp boosted its stake in shares of Ultragenyx Pharmaceutical by 31.7% during the 2nd quarter. Truist Financial Corp now owns 19,613 shares of the biopharmaceutical company’s stock worth $905,000 after purchasing an additional 4,726 shares during the last quarter. Privium Fund Management B.V. boosted its stake in shares of Ultragenyx Pharmaceutical by 1.4% during the 2nd quarter. Privium Fund Management B.V. now owns 112,241 shares of the biopharmaceutical company’s stock worth $5,236,000 after purchasing an additional 1,500 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Ultragenyx Pharmaceutical by 33.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 951 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 239 shares during the last quarter. DNB Asset Management AS acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth about $546,000. Finally, Pictet Asset Management SA boosted its stake in shares of Ultragenyx Pharmaceutical by 314.6% during the 1st quarter. Pictet Asset Management SA now owns 334,033 shares of the biopharmaceutical company’s stock worth $13,395,000 after purchasing an additional 253,463 shares during the last quarter. 96.37% of the stock is owned by institutional investors and hedge funds.
Ultragenyx Pharmaceutical Stock Performance
Shares of Ultragenyx Pharmaceutical stock opened at $39.97 on Friday. Ultragenyx Pharmaceutical has a one year low of $31.52 and a one year high of $54.98. The firm has a fifty day moving average of $36.06 and a two-hundred day moving average of $41.53.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- Five stocks we like better than Ultragenyx Pharmaceutical
- What Is Dividend Yield and How Do You Calculate It?
- 3 large caps with red hot RSIs with upside
- The Dividend Kings With Highest Yield
- Johnson Controls International: Nothing but upside for investors
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.